
Opinion|Videos|May 26, 2025
Decision-Making in Small Renal Masses
Explore the role of biopsies in managing ccRCC, especially in elderly patients, to optimize treatment decisions and preserve kidney function.
Advertisement
Episodes in this series

Clinical Utility of Renal Mass Biopsy
Main Discussion Topics:
- Biopsy may be more useful in patients with comorbidities where benign diagnosis would change management.
- Higher utility when nephron-sparing surgery is unlikely and nephrectomy would significantly impact renal function
- Patient preferences regarding surveillance vs intervention play an important role.
- Approximately 15% of radical nephrectomies for tumors that are 7 cm or larger were found to be oncocytoma or chromophobe renal cell carcinoma, where partial nephrectomy would have been appropriate.
Key Points for Physicians:
- Consider biopsy when management would change based on histology.
- Higher value in patients with impaired renal function or when radical nephrectomy is likely
- Biopsy can prevent unnecessary nephron loss in select cases.
- Patient-specific considerations should guide biopsy decisions.
Notable Insights:
Biopsy has particular value when nephron preservation is critical and when radical nephrectomy is likely based on tumor characteristics.
Clinical Significance:
Selective use of renal mass biopsy can prevent unnecessary nephron loss and guide appropriate therapy in challenging clinical scenarios.
Advertisement
Related to this article

Aaron Berger, MD, discusses patient selection for ARPI treatment holidays, monitoring during interruptions, and the role of testosterone recovery in interpreting PSA kinetics.

Paras H. Shah, MD, recaps data on emerging agents in high-risk NMIBC from the 2026 AUA North Central Section Meeting.

Five-year follow-up data show durable responses with UGN-101 in patients with low-grade upper tract urothelial carcinoma who achieved an initial complete response.

Tamim Niazi, MDCM, reviews DASL-HiCaP findings showing improved metastasis-free survival with darolutamide added to ADT and radiation therapy.

Chad Ritch, MD, discusses differences between PSMA-PET imaging agents and the need for further evidence to guide clinical decision-making.

The final analysis confirmed PFS and response benefits in previously treated advanced clear cell renal cell carcinoma, but the OS difference did not cross the prespecified significance boundary.
Advertisement
Advertisement
Trending on Urology Times
1
Tamim Niazi, MDCM, reviews darolutamide data from DASL-HiCaP
2
UGN-101 shows durable responses in low-grade upper tract urothelial carcinoma
3
2026 AUA North Central Section Meeting: Updates in high-risk NMIBC
4
ESMO 2026 On Location - Why pCR is not the whole story in cisplatin-ineligible MIBC
5

